Open AccessReal-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients
Author(s) -
Abhishek De,
Kiran Godse,
Dhiraj Dhoot,
Aarti Sarda
Publication year - 2021
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_771_20
Subject(s) - medicine , tolerability , dermatology life quality index , quality of life (healthcare) , refractory (planetary science) , antihistamine , medical record , retrospective cohort study , adverse effect , anesthesia , physics , nursing , disease , astrobiology
Second-generation H1-antihistamines (SGAHs) are the mainstay of treatment of chronic spontaneous urticaria (CSU). Bilastine, newer non-sedating SGAHs, was recently introduced in India after the approval of the Drugs Controller General of India. There is a paucity of evidence about the long-term efficacy and safety of Bilastine in Indian patients. We undertook this study to find the long-term efficacy and tolerability of Bilastine in patients with CSU in India.